West Pharmaceutical Services Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $194.2M | $1.17B | $169.4M |
| Jun 2017 | $195.7M | $1.24B | $226.6M |
| Sep 2017 | $196.6M | $1.32B | $269.3M |
| Dec 2017 | $197.0M | $1.28B | $235.9M |
| Mar 2018 | $198.0M | $1.31B | $199.8M |
| Jun 2018 | $196.4M | $1.28B | $225.5M |
| Sep 2018 | $196.2M | $1.35B | $297.3M |
| Dec 2018 | $196.0M | $1.40B | $337.4M |
| Mar 2019 | $195.5M | $1.37B | $265.5M |
| Jun 2019 | $196.0M | $1.45B | $326.7M |
| Sep 2019 | $195.1M | $1.49B | $396.0M |
| Dec 2019 | $255.0M | $1.57B | $439.1M |
| Mar 2020 | $254.4M | $1.49B | $335.3M |
| Jun 2020 | $253.9M | $1.61B | $445.9M |
| Sep 2020 | $253.4M | $1.72B | $519.4M |
| Dec 2020 | $252.9M | $1.85B | $615.5M |
| Mar 2021 | $252.3M | $1.83B | $483.7M |
| Jun 2021 | $251.8M | $2.03B | $576.2M |
| Sep 2021 | $209.9M | $2.20B | $688.0M |
| Dec 2021 | $208.8M | $2.34B | $762.6M |
| Mar 2022 | $208.3M | $2.33B | $667.7M |
| Jun 2022 | $207.8M | $2.42B | $718.5M |
| Sep 2022 | $207.2M | $2.47B | $729.0M |
| Dec 2022 | $206.7M | $2.68B | $894.3M |
| Mar 2023 | $206.1M | $2.78B | $886.3M |
| Jun 2023 | $205.6M | $2.75B | $796.3M |
| Sep 2023 | $152.1M | $2.87B | $898.6M |
| Dec 2023 | $72.8M | $2.88B | $853.9M |
| Mar 2024 | $72.8M | $2.68B | $601.8M |
| Jun 2024 | $72.9M | $2.58B | $446.2M |
| Sep 2024 | $202.6M | $2.75B | $490.9M |
| Dec 2024 | $202.6M | $2.68B | $484.6M |
| Mar 2025 | $202.6M | $2.68B | $404.2M |
| Jun 2025 | $202.6M | $2.93B | $509.7M |
| Sep 2025 | $202.7M | $3.05B | $628.5M |
| Dec 2025 | $202.8M | $3.18B | $791.3M |
| Mar 2026 | $202.8M | $2.99B | $521.4M |
| Jun 2026 | $202.9M | $2.99B | $435.8M |